Results for tag: "Ninlaro"

Ninlaro (Ixazomib) is a drug used to treat multiple myeloma, a type of cancer that affects the bone marrow. It is a proteasome inhibitor, meaning it works by blocking the activity of proteasomes, which are proteins that help cancer cells survive and grow. Ninlaro is approved by the US Food and Drug Administration (FDA) for use in combination with other drugs to treat multiple myeloma in adults who have received at least one prior therapy. Ninlaro is part of a growing market of leukemia drugs, which includes other proteasome inhibitors such as Velcade (bortezomib) and Kyprolis (carfilzomib). These drugs are used to treat multiple myeloma and other types of leukemia, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Other drugs in this market include immunomodulators, monoclonal antibodies, and targeted therapies. Some companies in the Ninlaro market include Takeda Pharmaceuticals, which manufactures the drug, as well as Bristol-Myers Squibb, Celgene, and Novartis. These companies are involved in the research, development, and marketing of Ninlaro and other leukemia drugs. Show Less Read more